Board of Directors
Mr. Kureshy, the Company's Founder, has been Chairman, President and Chief Executive Officer of AutoGenomics since its founding in April 1999. Mr. Kureshy has over 30 years of entrepreneurial leadership experience in the healthcare industry. Mr. Kureshy served as President and Chief Executive Officer of Sequenom, Inc. from 1996 to 1997, and as President of Behring Diagnostics, Inc. and PB Diagnostics Systems, Inc. from 1992 to 1996, where he set up the infrastructure to design, develop, manufacture and market platform technologies in the areas of chemistry, immunoassays and DNA analysis. Mr. Kureshy also spent 12 years at Abbott Laboratories from 1976 to 1987, where he held various management positions. Mr. Kureshy holds undergraduate degrees in physics, chemistry and mathematics from Karachi University, an undergraduate degree in engineering from Northrop University, and has completed graduate engineering studies. He was awarded an M.B.A. from Southern Methodist University.
Stephen D. Allison
Mr. Allison has over 25 years of experience advising and working for organizations in the healthcare and technology sectors and is currently an independent business consultant. From 2006 to 2007, Mr. Allison was Vice President, Chief Financial Officer of Gensym Corporation, a leading provider of software and services for mission-critical solutions in real time. Prior to Gensym, he was CFO for Webhire, Inc. from 2000 to 2003, PRI Automation from 1997 to 2000, and Helix Technology from 1995 to 1997. From 1991 until 1995, Mr. Allison was Vice President, Finance for Behring Diagnostics, Inc. an international company engaged in the development, manufacture, and sale of immunoassay systems. Mr. Allison holds a B.A. degree in Economics from Columbia University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.
Laurence M. Demers, Ph.D., DABCC, FACB
Dr. Demers, DABCC, FACB is Distinguished Professor of Pathology and Medicine at the M. S. Hershey Medical Center of the Pennsylvania State University, where he has taught since 1973. Dr. Demers is a diplomat of the American Board of Clinical Chemistry, a fellow of the National Academy of Clinical Biochemistry, a past president of the American Association for Clinical Chemistry as well as of the National Academy of Clinical Biochemistry, the founding director of Clinical Chemistry at the M.S. Hershey Medical Center, a Director of the Core Endocrine Laboratory in the Pennsylvania State University Hospital and a former director of the Pennsylvania State Clinical Research Center Core Laboratory. His primary research interests have been in the areas of molecular diagnostics, laboratory automation, thyroid disease, metabolic bone disease, and breast cancer. Dr. Demers has had extensive experiences as principal investigator of clinical trials for both the pharmaceutical and in vitro diagnostic industry. Dr. Demers holds an A.B. in biology from Merrimack College and a Ph.D. in biochemistry from State University of New York. Dr. Demers recently served as Chairman of the Board of Trustees of Merrimack College, North Andover, MA from 2007 to 2010 and was awarded an honorary Doctor of Science by Merrimack College in 2011.
Thomas V. Hennessey, Jr.
Mr. Hennessey has served as a Director of AutoGenomics since 2001. He joined AutoGenomics in January 2008 as Chief Operating Officer and Chief Financial Officer and served in those capacities until August 2013. Mr. Hennessey served as AutoGenomics' Chief Financial Officer as an independent contractor in December 2007 and as a non-employee director from January 2007 through November 2007. Mr. Hennessey has 35 years of experience in the medical and technology industries. Mr. Hennessey was an independent consultant to AutoGenomics from January 2003 until December 2007. From 2001 until 2003, he was Chief Operating Officer and Chief Financial Officer of Photovac, Inc. He has also served as Chief Operating Officer and Chief Financial Officer for several public and private start-up companies, including Behring Diagnostics, Inc., AutoImmune, Inc., Medical Diagnostics, Inc., Cambridge Heart, Inc., and Sonamed Corporation. Mr. Hennessey received a S.B. and a S.M. degree in mechanical engineering from Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Adam Levinson is the Founder, Managing Partner and CEO of Graticule Asset Management Asia, an independently owned Singapore-based alternative investment management firm with offices in Singapore, London, New York and San Francisco since January 2015. Previously, Mr. Levinson was the Chief Investment Officer and Founder of the Fortress Asia Macro Fund, Co-Chief Investment Officer of the Fortress Macro Funds and Chief Executive Officer of Fortress Investment Group (Singapore) Pte. Ltd. from June 2002 to January 2015. Mr. Levinson was also a member of the Management Committee of Fortress Investment Group. Prior to joining Fortress, Mr. Levinson was a fund manager at Tudor Investment Corporation and a proprietary trader for ten years at Goldman, Sachs & Co. Additionally, Mr. Levinson was the Head of Foreign Exchange at Goldman Sachs Japan from 1998 to 1999. Additionally, Mr. Levinson is a member of the Board of Directors at Fortress Investment Group as an Independent Director. Mr. Levinson received a B.A. in Government, magna cum laude, Phi Beta Kappa from Cornell University.
Peter Wilding, Ph.D., FACB
Dr. Wilding is professor emeritus in the department of pathology and laboratory medicine at the University of Pennsylvania Medical Center in Philadelphia since 2003, where he was director of clinical chemistry from 1986 to 2002. For the past 20 years, he has concentrated on the creation of new technology involving microfabricated devices now known as microchips for clinical analyses. Dr. Wilding has held many offices in organizations associated with laboratory medicine, including that of President of the American Association of Clinical Chemistry and has served as an adviser or consultant to the U.K. Department of Health, World Health Organization, International Federation of Clinical Chemistry and Laboratory Medicine, National Institutes of Health, and National Academy of Sciences. He is also an Honorary Professor of the West China University of Medical Sciences in Chengdu, China. Dr. Wilding is a Fellow of the Royal College of Pathologists (United Kingdom), the Royal Society of Chemistry (United Kingdom), and the National Academy of Clinical Biochemistry. He was certified by the American Board of Bioanalysis as a High Complexity Clinical Laboratory Director. Dr. Wilding received his B.Sc. with Honors in Medical Biochemistry in 1961 and his Ph.D. in Clinical Chemistry in 1965, both from the University of Birmingham, UK.